Immodulon CEO speaks at Europe’s leading biopartnering and investment conference

From 8th-10th May 2017, Immodulon’s Chief Executive Officer, Linda Summerton, attended OBN BioTrinity 2017, Europe’s leading biopartnering and investment conference.

This conference is the largest of its type in the UK and will be attended by a range of global life science investors, pharma executives and CEOs of emerging companies seeking to secure investment and grow their networks. On 10th May at 8:00 am Linda gave a short presentation on her experiences and dealings with sourcing funding for biotech companies, before taking her place on a panel discussion entitled, “Pharma Licensing – Pros and Cons of Early Stage Collaboration with Big Pharma.”

OBN BioTrinity 2017